livehealth.store

Esperion recalls

Esperion has 2 recalls on record with the FDA and USDA, the earliest in 2023 and the latest reported on 24 Apr 2024. The most frequent reason is potency & assay.

Total recalls2since 2023

Last 12 months0reported

Class I00% of total

Ongoing0latest 24 Apr 2024

Recalls per month, last 24 months

click a bar for that month

0Oct '24 0 0 0Jan '25 0 0 0Apr 0 0 0Jul 0 0 0Oct 0 0 0Jan '26 0 0 0Apr 0 0 0Jul 0 0

Severity split

Class I 0 0%Class II 0 0%Class III 2 100%

Why esperion is recalled

Potency & Assay2100%

Product types

Cholesterol Medication2100%

By year

2024150%
2023150%

All esperion recalls, newest first

2 total

Reported	Class	Recall	Company	Reason	Where
24 Apr 2024Drug	CLASS III	Nexlizet (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg recalledNexlizet	Esperion	Potency & Assay	Nationwide
13 Sep 2023Drug	CLASS III	Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg recalled by EsperionNexlizet	Esperion	Potency & Assay	Nationwide

About this list

Records come from FDA enforcement reports and USDA FSIS notices, grouped by normalised name. A company operating under several names may appear more than once.